$119,160,691
to SHIONOGI INC
LATE-STAGE DEVELOPMENT, FDA MARKETING AUTHORIZATION, PROCUREMENT, AND STOCKPILE OF ANTIBIOTICS FOR THE TREATMENT OF DRUG-RESISTANT SECONDARY BACTERIAL INFECTIONS AND/OR THE TREATMENT OR PEP OF INFECTIONS CAUSED BY BIOTHREAT PATHOGENS.
Verbatim from USAspending.gov. Capitalization, abbreviations, and codes are unchanged.
What the model surfaced from this award
Late-stage development, FDA approval, procurement, and stockpiling of antibiotics for drug-resistant bacterial infections and biothreat pathogens.
Addresses critical gap in medical countermeasures for antimicrobial resistance and biological threats to national security and public health.
Signals government commitment to domestic antibiotic manufacturing capacity and strategic reserves independent of foreign suppliers.
Reduces U.S. reliance on Chinese pharmaceutical APIs and manufacturing for critical antibiotics; strengthens domestic biodefense capabilities.
Generated by award_classification v2.0.0 via claude-haiku-4-5-20251001 on 2026-05-15. Cost: $0.002246.
- USAspending.gov — all awards for this UEI →
- SAM.gov entity registration →
- Award record ingested from usaspending. Source identifier CONT_AWD_75A50126C00004_7505_-NONE-_-NONE-.
The Buildout does not edit federal records. Any inaccuracy reflects the upstream source; it will update here when corrected there.